1100
(i) chemo-endocrine therapy with CMF plus low-dose prednisone (p) and tamoxifen (T) (CMFpT regimen for twelve 1-month cycles); (ii) endocrine therapy alone with pT for the same duration; or (iii) no adjuvant therapy.2 All patients had had at least a total mastectomy and axillary clearance. At a median follow-up of receive
108 months, the 9-year disease-free survival rates were 41 %, 31 %, and 19%, respectively (p
(i) chemo-endocrine therapy with CMF plus low-dose prednisone (p) and tamoxifen (T) (CMFpT regimen for twelve 1-month cycles); (ii) endocrine therapy alone with pT for the same duration; or (iii) no adjuvant therapy.2 All patients had had at least a total mastectomy and axillary clearance. At a median follow-up of receive
108 months, the 9-year disease-free survival rates were 41 %, 31 %, and 19%, respectively (p
